---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-135768"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:11:37.769558+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027

## Summary
- BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.
- BBI-355 Phase 1/2 POTENTIATE trial on track for initial clinical data readout in H2 2025; enrollment ongoing.
- Third ecDTx program targeting a kinesin for ecDNA segregation; development candidate nomination expected mid-2025, IND in H1 2026.
- CMO Klaus Wagner and CBO Neil Abdollahian departing; James Freddo named Interim CMO while search for permanent CMO begins.
- Cash, equivalents, and short-term investments sufficient to fund operations into 2027 through anticipated milestones.

## SEC filing metadata
- accession: 0000950170-24-135768
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/0000950170-24-135768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017024135768/bold-20241206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-135768
- JSON: https://secwatch.observer/filing/0000950170-24-135768.json
- Plain text: https://secwatch.observer/filing/0000950170-24-135768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.